Patient characteristics (N = 17)
| Characteristics . | Data . |
|---|---|
| Age, median (range), y | 58 (35-77) |
| Females/males, n | 5/12 |
| Hematological malignancies | 15 (88) |
| Diffuse large B-cell lymphoma | 4 (28) |
| Mantle cell lymphoma | 3 (20) |
| Follicular lymphoma | 3 (20) |
| Chronic lymphocytic leukemia/Richter syndrome | 3 (20) |
| Marginal zone lymphoma | 1 (6) |
| Waldenström macroglobulinemia | 1 (6) |
| Nonhematological malignancies | 2 (12) |
| Multiple sclerosis | 1 (6) |
| Common variable immune deficiency | 1 (6) |
| Disease status | |
| Complete response | 11 (65) |
| Partial response | 3 (18) |
| Progressive disease | 2 (12) |
| Not attributed | 1 (5) |
| Last chemotherapy | |
| R-chemotherapy* | 6 (35) |
| Rituximab/obinutuzumab maintenance | 7 (42) |
| Other† | 3 (18) |
| Not attributed | 1 (5) |
| Previous treatment with anti-CD20 therapy | 15 (88) |
| Cycles of anti-CD20 therapy, median (range) | 7 (4-18) |
| Gammaglobulinemia, median (range), g/L‡ | 3.5 (1.8-14) |
| Time between COVID-19 symptoms onset and last anti-CD20 therapy, median (range), mo | 4 (3-6) |
| COVID-19 severity (WHO score) | |
| 4 | 5 (29) |
| 5-6 | 10 (59) |
| ≥7 | 2 (12) |
| Previous COVID-19–specific treatments | 11 (65) |
| Steroids | 8 (72) |
| Hydroxychloroquine | 5 (45) |
| Tocilizumab | 4 (36) |
| Remdesivir | 3 (27) |
| Lopinavir-ritonavir | 2 (18) |
| Time from COVID-19 symptoms onset to CPT, median (range), d | 56 (7-83) |
| Oxygen weaning (NIV or nasal prong) | 10 (100) |
| Time for oxygen weaning after CPT, median (range), d | 5 (1-45) |
| Length of hospital stay after CPT, median (range), d | 7 (2-14) |
| Overall survival | 16 (94) |
| Characteristics . | Data . |
|---|---|
| Age, median (range), y | 58 (35-77) |
| Females/males, n | 5/12 |
| Hematological malignancies | 15 (88) |
| Diffuse large B-cell lymphoma | 4 (28) |
| Mantle cell lymphoma | 3 (20) |
| Follicular lymphoma | 3 (20) |
| Chronic lymphocytic leukemia/Richter syndrome | 3 (20) |
| Marginal zone lymphoma | 1 (6) |
| Waldenström macroglobulinemia | 1 (6) |
| Nonhematological malignancies | 2 (12) |
| Multiple sclerosis | 1 (6) |
| Common variable immune deficiency | 1 (6) |
| Disease status | |
| Complete response | 11 (65) |
| Partial response | 3 (18) |
| Progressive disease | 2 (12) |
| Not attributed | 1 (5) |
| Last chemotherapy | |
| R-chemotherapy* | 6 (35) |
| Rituximab/obinutuzumab maintenance | 7 (42) |
| Other† | 3 (18) |
| Not attributed | 1 (5) |
| Previous treatment with anti-CD20 therapy | 15 (88) |
| Cycles of anti-CD20 therapy, median (range) | 7 (4-18) |
| Gammaglobulinemia, median (range), g/L‡ | 3.5 (1.8-14) |
| Time between COVID-19 symptoms onset and last anti-CD20 therapy, median (range), mo | 4 (3-6) |
| COVID-19 severity (WHO score) | |
| 4 | 5 (29) |
| 5-6 | 10 (59) |
| ≥7 | 2 (12) |
| Previous COVID-19–specific treatments | 11 (65) |
| Steroids | 8 (72) |
| Hydroxychloroquine | 5 (45) |
| Tocilizumab | 4 (36) |
| Remdesivir | 3 (27) |
| Lopinavir-ritonavir | 2 (18) |
| Time from COVID-19 symptoms onset to CPT, median (range), d | 56 (7-83) |
| Oxygen weaning (NIV or nasal prong) | 10 (100) |
| Time for oxygen weaning after CPT, median (range), d | 5 (1-45) |
| Length of hospital stay after CPT, median (range), d | 7 (2-14) |
| Overall survival | 16 (94) |
Unless otherwise noted, data are n (%).
NIV, noninvasive ventilation; WHO, World Health Organization.
R-chemotherapy was composed of several regimens combining rituximab with bendamustine (2 patients), high-dose aracytine + cisplatin (2 patients), fludarabine + cyclophosphamide (1 patient), and ifosfamide + cyclophosphamide + etoposide (2 patients).
Other treatments were ibrutinib (1 patient), venetoclax (1 patient), or chimeric antigen receptor T cells (1 patient).
Two patients had gamma globulin supplementation. The normal range for gamma globulin is 7 to 14 g/L.